Exicure (XCUR) Competitors $3.16 +0.13 (+4.29%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrends XCUR vs. XFOR, MNOV, VTGN, ELUT, ALRN, CTMX, IOBT, PLX, CMRX, and INCRShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include X4 Pharmaceuticals (XFOR), MediciNova (MNOV), Vistagen Therapeutics (VTGN), Elutia (ELUT), Aileron Therapeutics (ALRN), CytomX Therapeutics (CTMX), IO Biotech (IOBT), Protalix BioTherapeutics (PLX), Chimerix (CMRX), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry. Exicure vs. X4 Pharmaceuticals MediciNova Vistagen Therapeutics Elutia Aileron Therapeutics CytomX Therapeutics IO Biotech Protalix BioTherapeutics Chimerix InterCure Exicure (NASDAQ:XCUR) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Which has stronger valuation and earnings, XCUR or XFOR? Exicure has higher revenue and earnings than X4 Pharmaceuticals. Exicure is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$28.83M0.19-$16.91M-$4.55-0.69X4 Pharmaceuticals$563K155.33-$101.17M$0.086.49 Do analysts rate XCUR or XFOR? X4 Pharmaceuticals has a consensus price target of $3.67, suggesting a potential upside of 606.49%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AX4 Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals have more ownership in XCUR or XFOR? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 3.9% of Exicure shares are owned by company insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor XCUR or XFOR? In the previous week, X4 Pharmaceuticals had 1 more articles in the media than Exicure. MarketBeat recorded 2 mentions for X4 Pharmaceuticals and 1 mentions for Exicure. Exicure's average media sentiment score of 0.00 equaled X4 Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, XCUR or XFOR? Exicure has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Is XCUR or XFOR more profitable? X4 Pharmaceuticals' return on equity of -163.17% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -288.02% -71.17% X4 Pharmaceuticals N/A -163.17%-54.32% Does the MarketBeat Community favor XCUR or XFOR? X4 Pharmaceuticals received 64 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 66.36% of users gave X4 Pharmaceuticals an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformExicureOutperform Votes947.37% Underperform Votes1052.63% X4 PharmaceuticalsOutperform Votes7366.36% Underperform Votes3733.64% SummaryX4 Pharmaceuticals beats Exicure on 11 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.47M$7.02B$5.40B$8.53BDividend YieldN/A7.97%5.15%4.14%P/E Ratio-0.699.53113.7615.14Price / Sales0.19385.111,483.0493.53Price / CashN/A47.3339.7134.04Price / Book1.815.324.665.01Net Income-$16.91M$153.56M$119.06M$225.46M7 Day Performance33.33%0.12%0.79%0.37%1 Month Performance13.67%15.23%5.65%3.57%1 Year Performance393.36%41.16%36.80%29.42% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.7367 of 5 stars$3.16+4.3%N/A+409.7%$5.47M$28.83M-0.6950XFORX4 Pharmaceuticals4.3027 of 5 stars$0.49flat$3.67+654.5%-30.9%$81.62M$563,000.006.0880News CoverageMNOVMediciNova0.1688 of 5 stars$1.66-4.0%N/A-11.7%$81.42M$1M-10.3710Analyst ForecastVTGNVistagen Therapeutics2.5445 of 5 stars$3.01-0.7%$13.50+348.5%+2.0%$81.35M$971,000.00-2.0340News CoveragePositive NewsELUTElutia2.7821 of 5 stars$3.31+2.5%$10.00+202.1%+141.7%$80.34M$24.99M-1.16180Short Interest ↑News CoverageALRNAileron Therapeutics3.8466 of 5 stars$3.72-0.3%$19.00+411.4%+200.9%$80.30MN/A-1.149Upcoming EarningsShort Interest ↓News CoverageCTMXCytomX Therapeutics4.2319 of 5 stars$1.03-4.6%$5.77+460.4%-2.8%$80.26M$119.57M7.36170Upcoming EarningsNews CoverageIOBTIO Biotech3.3571 of 5 stars$1.21-0.8%$9.33+671.3%+36.8%$79.72MN/A-0.8430Short Interest ↓Positive NewsPLXProtalix BioTherapeutics1.9046 of 5 stars$1.08+4.9%$10.00+825.9%-23.1%$79.18M$38.05M-5.40200Gap UpCMRXChimerix4.1022 of 5 stars$0.87flat$8.50+874.3%+3.1%$78.19M$144,000.00-0.9272Upcoming EarningsNews CoverageINCRInterCure1.2436 of 5 stars$1.70-5.6%N/A+72.3%$77.47M$96.61M0.00350Short Interest ↓Positive News Related Companies and Tools Related Companies X4 Pharmaceuticals Alternatives MediciNova Alternatives Vistagen Therapeutics Alternatives Elutia Alternatives Aileron Therapeutics Alternatives CytomX Therapeutics Alternatives IO Biotech Alternatives Protalix BioTherapeutics Alternatives Chimerix Alternatives InterCure Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XCUR) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
